Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann has maintained a Buy rating on Corvus Pharma and raised the price target from $12 to $21, indicating a positive outlook for the company's stock.
September 16, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ladenburg Thalmann has increased its price target for Corvus Pharma from $12 to $21, maintaining a Buy rating. This suggests a positive outlook and potential stock price increase.
The increase in price target from $12 to $21 by Ladenburg Thalmann, along with the maintained Buy rating, indicates strong confidence in Corvus Pharma's future performance. This is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100